期刊文献+

加替沙星序贯治疗下呼吸道感染疗效评价 被引量:1

Clinical Evalution of Sequential Therapy of Gatifloxacin and Levofloxacin on Treatment of Lower Respiratory Tract Infection
暂未订购
导出
摘要 目的:评价加替沙星静滴、加替沙星静滴和左氧氟沙星口服序贯治疗下呼吸道感染的疗效和安全性。方法:将256例下呼吸道感染患者随机分为2组,其中对照组应用加替沙星注射液400 mg静滴,qd;序贯组用加替沙星注射液400 mg静滴qd,3 d后改为口服左氧氟沙星片400 mg,qd,疗程均为7~14 d。结果:对照组和序贯组总有效率分别为89.84%与85.94%,细菌清除率分别为95.33%与92.45%,药物不良反应发生率分别为8.59%与7.81%,其结果均无经统计学差异(P>0.05)。结论:加替沙星、左氧氟沙星序贯治疗下呼吸道感染具有与单用加替沙星静滴相似的临床疗效,但比单用依从性好。 Objective: To evaluate the clinical efficacy and safety of sequential therapy of gatifloxacin and levofloxacin in the treatment of lower respiratory tract infections(LRTI). Method: A total of 256 in-patients with LRTI were divided into two groups randomly, the control group used gatifloxacin 400 mg ivd, qd and the sequatial group used gatifloxacin 400 mg ivd,qd once daily for 3 days and subsequently oral levofloxacin 400 mg qd. The total duration of therapy was 7 - 14 days. Result: The clinical total efficacy rate was 89.84% in control group, and 85.94% in sequential group, respectively. The bacterial eradication rate was 95.33% and 92.45% respectively, and the adverse drug reaction rate was 8.59% and 7.81% respectively. There were no statistical difference between two groups ( P 〉 0.05 ). Conclusion : The efficacy of sequential therapy with gatifloxacin and levofloxaxin is equivalence to monotherapy of gatifloxacin.
出处 《中国药师》 CAS 2007年第11期1125-1127,共3页 China Pharmacist
关键词 加替沙星 左氧氟沙星 下呼吸道感染 序贯治疗 Gatifloxacin Levofloxacin Lower respiratory tract infections Sequential therapy
  • 相关文献

参考文献11

  • 1中华人民共和国卫生部药政局.抗菌药物临床研究指导原则[S].1993.
  • 2Paladino JA.Phanancoecomics of Antimicrobial Therapy.[J].Am J HealthSyst Pharm,1999,56(22 Suppl 3):s25
  • 3Blasi F,Tarsia P.Cosentini R,el al.Therapeutic potential of the new quinolones in the treatment of lower respiratory tract infections[J].Expert opin Investig Drugs,2003,12(7):1165
  • 4Lode H,Allewelt M.Role of newer fluoroquinolones in lower respiratory tract infections[J].Antimicrob.Chemother,2002,49(5):709
  • 5Ortqvist A.Treatment of community-acquired lower respiratory tract infections in adults[J].Eur.Respir.J,2002,20(Suppl 36):s40
  • 6Perry CM,Ormord D.Hurst M,et al.Gatifloxacin:a review of its use in the management of bacterial infections[J].Drugs,2002,62(1):169
  • 7Sullivan JG,MeEIroy AD,Honainger et al.Treating community-acquired pneumonia with once-daily gatifloxacin vs.once-daily levofloxaein[J].Journal of Respiratory Diseases,1999,20(Suppl 5):49
  • 8Fish DN.Fluoroquinolone adverse effects and drug interactions[J].Pharmacotherapy,2001;21(10 pt 2):s253
  • 9Marrie TJ,Lau CY,Wheeler SL,et al.A controlled trial of a critical pathway for treatment of community-acquired pneumonia.CAPITAL Study Investigators.Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin[J].JAMA,2000,283(6):749
  • 10JA Ramirez,L Srinath,S Ahkes,et al.Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia[J].Arch Intern Med,1995,155(12):1273

共引文献7

同被引文献8

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部